In the News

Cleveland Clinic Brings The Promise of Telemedicine To Reality

Several people I know who have retired to Florida in recent years still return to the New York area a couple of times a year just to see their doctors. In the majority of cases, these are simply routine follow-ups. But in the era of expanding healthcare technology, smartphones, and tablets, this all seems pretty inefficient, not to mention expensive. Why not just reach out to your practitioner remotely? That’s been the promise of telemedicine for several decades. Now institutions like the Cleveland Clinic are moving it from trial into practice. At the recent Techonomy Health Conference in New York, we had the opportunity to sit down with Dr. Brian Donley, Chief of Staff of the Cleveland Clinic, to speak about their telemedicine program.

Cleveland Clinic-led Study Finds That New Blood Test is More Accurate in Predicting Overall Risk of Prostate Cancer than Standard Prostate-Specific Antigen (PSA)

A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures – distinguishing cancer from benign conditions, and identifying patients with high-risk disease.

ERT Acquires Imaging Solution from Cleveland Clinic

ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced the acquisition of ImageIQ, originally established as Cleveland Clinic’s Biomedical Imaging and Analysis Center. The acquisition enables ERT to offer advanced, end-to-end clinical trial imaging analysis using best-in-class technology that delivers compliant data for use in clinical development.

Cleveland HeartLab Adds Two Additional Patents to its Extensive Intellectual Property Position for the Myeloperoxidase (MPO) test, a key predictor of Major Cardiac Events

Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that two new patents for Myeloperoxidase (MPO) testing have been issued: U.S. Patent No. 9,581,597 and U.S. Patent No. 9,612,242. Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of patents including these two newly issued patents. Originally discovered and developed at the Cleveland Clinic, MPO testing has been recognized in over 100 peer-reviewed publications as a key measure of vascular inflammation, which plays a key role in CVD and cardiovascular events. These new patents will add to Cleveland HeartLab's already existing portfolio of intellectual property rights, which includes 26 issued patents and an additional 15 pending patent applications.

Innovation center is looking to keep blood flowing

In the decade since its founding, the Global Cardiovascular Innovation Center has reached some milestones its leaders are quick to tick off — and now the center is considering how to sustain its operations as its original funding source wanes.